{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:47:12Z","timestamp":1785869232492,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113\\u20132926-I-038\\u2013501-G"],"award-info":[{"award-number":["113\\u20132926-I-038\\u2013501-G"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114\\u20132628-B-038\\u2013008-MY3"],"award-info":[{"award-number":["114\\u20132628-B-038\\u2013008-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114\\u20132320-B-038\\u2013061"],"award-info":[{"award-number":["114\\u20132320-B-038\\u2013061"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113\\u20132636-B-038\\u2013001"],"award-info":[{"award-number":["113\\u20132636-B-038\\u2013001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113\\u20132320-B-182A-008-MY3"],"award-info":[{"award-number":["113\\u20132320-B-182A-008-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112\\u20132113-M-038\\u2013001"],"award-info":[{"award-number":["112\\u20132113-M-038\\u2013001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113\\u20132320-B-182A-001"],"award-info":[{"award-number":["113\\u20132320-B-182A-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["DP2-TMU-114-C-01"],"award-info":[{"award-number":["DP2-TMU-114-C-01"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118816","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:43:45Z","timestamp":1764092625000},"page":"118816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A novel dual CDC25-HDAC inhibitor suppresses glioblastoma progression via chromosomal passenger complex disruption"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9721-9774","authenticated-orcid":false,"given":"Richa","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-2304","authenticated-orcid":false,"given":"Bidyadhar","family":"Sethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Chi","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-5092","authenticated-orcid":false,"given":"Iin","family":"Narwanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Nepali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-0643","authenticated-orcid":false,"given":"Jian-Ying","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118816_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1586\/14737140.1.3.395","article-title":"Current epidemiological trends and surveillance issues in brain tumors","volume":"1","author":"Davis","year":"2001","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.biopha.2025.118816_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"26","key":"10.1016\/j.biopha.2025.118816_bib3","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"Stupp","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118816_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2018.10.013","article-title":"Approaches to physical stimulation of metallic nanoparticles for glioblastoma treatment","volume":"138","author":"Pinel","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib5","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist."},{"issue":"10","key":"10.1016\/j.biopha.2025.118816_bib6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.118816_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/15384047.2019.1599662","article-title":"Glioblastoma vs temozolomide: can the red queen race be won?","volume":"20","author":"Arora","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2025.118816_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib9","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118816_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/0019-509X.200658","article-title":"Cancer and cure: a critical analysis","volume":"53","author":"Roy","year":"2016","journal-title":"Indian J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118816_bib11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ceb.2006.02.003","article-title":"The when and wheres of CDC25 phosphatases","volume":"18","author":"Boutros","year":"2006","journal-title":"Curr. Opin. Cell Biol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118816_bib12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2174\/187152008786847693","article-title":"In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets","volume":"8","author":"Kiyokawa","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2025.118816_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/187152008786847738","article-title":"Is Cdc25 a druggable target?","volume":"8","author":"Lazo","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118816_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41388-018-0474-y","article-title":"An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia","volume":"38","author":"Swaroop","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118816_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.csbj.2018.06.001","article-title":"Lung cancer therapy targeting histone methylation: opportunities and challenges","volume":"16","author":"Chen","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.biopha.2025.118816_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/epi.2.3.5049","article-title":"Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment","volume":"2","author":"Martinez","year":"2007","journal-title":"Epigenetics"},{"key":"10.1016\/j.biopha.2025.118816_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-61779-612-8_8","article-title":"The epigenetics of brain tumors","volume":"863","author":"Dubuc","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118816_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2018.05.023","article-title":"Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K\/AKT and MEK\/ERK signaling pathways","volume":"1692","author":"Li","year":"2018","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.118816_bib19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00280-016-3188-2","article-title":"Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity","volume":"78","author":"Zhang","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118816_bib20","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient synthesis and bioevaluation of novel dual tubulin\/histone deacetylase 3 inhibitors as potential anticancer agents","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.biopha.2025.118816_bib21","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-022-02257-w","article-title":"HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells","volume":"41","author":"Wu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118816_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115054","article-title":"Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects","volume":"248","author":"Nepali","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2025.118816_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41419-021-04182-w","article-title":"Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118816_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113338","article-title":"Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: a preliminary attempt to unravel the enigma of glioblastoma","volume":"217","author":"Nepali","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118816_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa103","article-title":"Increased activation of HDAC1\/2\/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma","author":"Yang","year":"2020","journal-title":"Neuro Oncol."},{"issue":"11-12","key":"10.1016\/j.biopha.2025.118816_bib27","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s10495-024-02023-7","article-title":"Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer","volume":"29","author":"Sethy","year":"2024","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2025.118816_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.etap.2016.09.009","article-title":"Influence of silver and titanium dioxide nanoparticles on in vitro blood-brain barrier permeability","volume":"47","author":"Chen","year":"2016","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118816_bib29","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1021\/ci300124c","article-title":"A Bayesian approach to in silico blood-brain barrier penetration modeling","volume":"52","author":"Martins","year":"2012","journal-title":"J. Chem. Inf. Model"},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2025.118816_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107057","article-title":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","volume":"208","author":"El Omari","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118816_bib32","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.celrep.2018.03.039","article-title":"Identification of CDC25 as a common therapeutic target for triple-negative breast cancer","volume":"23","author":"Liu","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118816_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41419-025-07598-w","article-title":"CDC25A inhibition sensitizes melanoma cells to doxorubicin and NK cell therapy","volume":"16","author":"Gao","year":"2025","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.biopha.2025.118816_bib36","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2023.12996","article-title":"CDC25A inhibition suppresses cell proliferation and induces G(1)\/S\u2011phase cell cycle arrest in nasopharyngeal carcinoma","volume":"27","author":"Wang","year":"2023","journal-title":"Mol. Med. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2025.118816_bib37","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.xphs.2017.04.080","article-title":"Routes for drug translocation across the blood-brain barrier: exploiting peptides as delivery vectors","volume":"106","author":"Kristensen","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118816_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.biopha.2025.118816_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrm3474","article-title":"The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis","volume":"13","author":"Carmena","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118816_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2021.09.008","article-title":"Changing places: chromosomal passenger complex relocation in early anaphase","volume":"32","author":"Hadders","year":"2022","journal-title":"Trends Cell Biol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:23:12Z","timestamp":1778541792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S0753332225010108"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118816","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel dual CDC25-HDAC inhibitor suppresses glioblastoma progression via chromosomal passenger complex disruption","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118816","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118816"}}